Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roche Holding AGXSWX:RO -0.54%73 3-Year Dividend Growth Rate is 1.40% as of Jun. 2026, which is 80% below its 10-year median of 7.00. GuruFocus rates XSWX:RO with a GF Score™ of 73/100 and a GF Value™ of CHF270.14 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 352 Drug Manufacturers companies, Roche Holding AG ranks worse than 70.17% on this metric.
The historical rank and industry rank for Roche Holding AG's 3-Year Dividend Growth Rate or its related term are showing as below:
XSWX:RO'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 1.2 Med: 7 Max: 32
Current: 1.4
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Roche Holding AG was 32.00% per year. The lowest was 1.20% per year. And the median was 7.00% per year.
XSWX:RO's 3-Year Dividend Growth Rate is ranked worse than 70.17% of 352
companies
in the Drug Manufacturers industry
Industry Median: 7.7
vs XSWX:RO: 1.40
During the past 12 months, Roche Holding AG's average Dividends Per Share Growth Rate was 1.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 1.40% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 1.60% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 2.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of Roche Holding AG was 0.56. The lowest was 0.43. And the median was 0.48.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Roche Holding AG Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
CHF 9.800000
2026-03-12
2026-03-13
2026-03-16
Cash Dividend
annually
CHF:CHF 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Roche Holding AG's Dividend Yield (%) for Today is calculated as
Current Share Price is CHF371.60.
Roche Holding AG's Dividends per Share for the trailing twelve months (TTM) ended in Today is CHF9.8.
During the past 13 years, the highest Dividend Yield of Roche Holding AG was 4.37%. The lowest was 2.28%. And the median was 3.20%.
Warning Sign:
Roche Holding AG stock Dividend Yield % is close to 3-year low.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG 3-Year Dividend Growth Rate Related Terms>
XSWX:RO vs LLY, JNJ, ABBV: 3-Year Dividend Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG 3-Year Dividend Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's 3-Year Dividend Growth Rate falls into.
Roche Holding AG 3-Year Dividend Growth Rate Calculation
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 1.40% mean?
Roche Holding AG (XSWX:RO) has a 3-Year Dividend Growth Rate of 1.40% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Roche Holding AG and its competitors. This is 80% below median its historical median of 7.00. Over the past decade, Roche Holding AG's 3-Year Dividend Growth Rate has ranged from 1.20 to 32.00. According to the industry distribution chart, Roche Holding AG ranks #247 out of 352 companies in the Drug Manufacturers industry, placing it in the top 70.2%.
Is Roche Holding AG's 3-Year Dividend Growth Rate too high?
Roche Holding AG's current 3-Year Dividend Growth Rate of 1.40% is 80% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 32.00. The Drug Manufacturers industry median 3-Year Dividend Growth Rate is 7.70. Roche Holding AG's value of 1.40% is 81.8% below this industry median. Based on the distribution chart, Roche Holding AG ranks #247 out of 352 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's 3-Year Dividend Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #247 out of 352 companies for 3-Year Dividend Growth Rate. This places Roche Holding AG in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 7.70. Roche Holding AG's value of 1.40% is 81.8% below this benchmark. Historically, Roche Holding AG's own 3-Year Dividend Growth Rate has ranged from 1.20 to 32.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 7.70, Roche Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Drug Manufacturers company?
The median 3-Year Dividend Growth Rate among Drug Manufacturers companies is 7.70, based on 352 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current 3-Year Dividend Growth Rate of 1.40% is 81.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median 3-Year Dividend Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current 3-Year Dividend Growth Rate is 1.40%, which is 80% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF270.14, compared to a current price of CHF371.60 — trading 37.6% above its estimated fair value. The current 3-Year Dividend Growth Rate is 1.40%, which is 80% below median its 10-year median of 7.00 and 81.8% below the Drug Manufacturers industry median of 7.70. Roche Holding AG's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current 3-Year Dividend Growth Rate is 1.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF371.60 is trading 37.6% above its estimated GF Value™ of CHF270.14.
GuruFocus considers Roche Holding AG to be Significantly Overvalued.
Key valuation signals for XSWX:RO:
3-Year Dividend Growth Rate: 1.40% (80% below median its 10-year median of 7.00)
GF Value™: CHF270.14 vs. price of CHF371.60 (37.6% above fair value)
Industry Position: 81.8% below the Drug Manufacturers median (#247 of 352)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
73GF Score
Get the complete analysis for XSWX:RO
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
